Now Enrolling · The FIT Lipedema and Inflammation Program
Connective-tissue–aware GLP-1 care. Built for the patient most clinics miss.
A physician-run GLP-1 program designed specifically for patients with hypermobile EDS, MCAS, lipedema, and the overlapping connective-tissue conditions that make casual prescribing dangerous — and careful prescribing transformative.
· Monthly check-ins & labs
· Lean-mass preserving
· OxeFit training included
The Problem
Most GLP-1 prescribing isn’t built for your body.
Patients with hEDS, MCAS, and lipedema have unique vulnerabilities to GLP-1 medications that mass-market clinics and online prescribers are not equipped to manage. Real risks — well documented in the literature — that get worse, not better, when titration is fast and follow-up is minimal.
Gastroparesis stacks on dysmotility.
Up to half of hEDS patients have baseline delayed gastric emptying. GLP-1s slow it further. Aggressive titration can lead to intractable nausea, vomiting, and hospitalization.
Lean mass loss erodes joint stability.
Up to 40% of weight lost on GLP-1s can be lean body mass. In patients whose joints are stabilized by muscle, every kilogram lost is a measurable loss of joint protection.
Fascial pain after rapid fat loss.
In abnormal extracellular matrix, fascia remodels unevenly. The result is diffuse fascial pain, pulling, and worsening myofascial trigger points — underreported and clinically real.
The Program
The FIT Lipedema and Inflammation Program. FLIP, in five non-negotiables.
If GLP-1 medications are going to be safe and effective in the hypermobile patient, the program around the prescription matters more than the prescription itself. Here is how we built one.
Pillar 01
Physician-run titration, not algorithmic.
Every patient starts and advances under the direct supervision of Dr. Courseault. Slower than the manufacturer label. We under-titrate to find the lowest effective dose — not the highest tolerated one.
Pillar 02
Three transparent dose tiers.
Three monthly pricing tiers, disclosed up front in your consent and financial agreement. Placement is based on clinical need, tolerability, and metabolic response — not marketing pressure or volume incentives. See pricing below.
Pillar 03
Full lab evaluation, with optional GPS genomic testing.
Every FLIP patient receives a comprehensive baseline lab workup — lipids, fasting insulin, HbA1c, hsCRP, thyroid panel, electrolytes, renal function, B12, iron studies, and tryptase or inflammatory markers when indicated — with structured monthly re-evaluation. Patients can optionally add FIT GPS™, our genomic performance screen, to layer DNA-level insight on metabolism, recovery, and supplementation onto the metabolic panel. Strongly recommended for any patient choosing GLP-1 therapy.
Pillar 04
Body composition scale, included.
A clinical-grade scale to take home and track fat mass, lean mass, visceral fat, and segmental composition between visits. Lean mass is a primary safety endpoint — not a secondary one.
Pillar 05
OxeFit resistance training, included.
Every FLIP patient receives an OxeFit membership at FIT Therapeutics. The platform’s computer-controlled cable resistance lets us load hypermobile patients precisely without putting unstable joints into the positions that injure them — and capture the exact force, velocity, and power data we need to prove, visit over visit, that you are preserving and building lean mass during GLP-1 therapy.
Pricing
Three dose tiers. One transparent program.
Tier placement is clinical, not commercial. Every patient receives the same monthly check-in cadence, the same lab monitoring, the same body composition scale, and the same OxeFit membership — regardless of dose.
For patients beginning therapy, in early titration, or with significant tolerability concerns.
The maintenance range most patients settle into once early titration is complete.
Selected patients with clear indications for higher-dose therapy, monitored closely.
Every tier includes:
- Physician-run titration with Dr. Courseault
- Full baseline lab evaluation with structured monthly re-evaluation
- Monthly physician check-ins
- Clinical-grade body composition scale (yours to keep)
- OxeFit membership at FIT Therapeutics
- Direct coordination with your existing care plan
Who It’s For
FLIP is built for one kind of patient. Not all of them.
FLIP is for you if you have
The body this program was designed for.
- Lipedema (any stage), particularly with hypermobility, MCAS, or autonomic features
- Hypermobile EDS or HSD with metabolic, inflammatory, or weight-related symptoms unresponsive to standard care
- MCAS with significant systemic inflammation, especially with insulin resistance or refractory weight gain
- A history of unsupervised GLP-1 that was poorly tolerated or that failed — and you need a clinically rigorous reset
FLIP is not for you if you want
A fast-titration cosmetic prescription.
- The fastest, cheapest GLP-1 access available
- Monthly auto-shipped pens with minimal clinical follow-up
- Cosmetic weight loss without consideration of joint stability, lean mass, or systemic inflammation
- An online intake with no in-person evaluation
There are clinics that do this. We are not one of them, and we will not become one.
Connected Care
FLIP doesn’t operate in isolation.
FLIP patients have access to the full clinical infrastructure of The Fascia Institute and Treatment Center® — the diagnostics, treatments, and specialty programs these patients already need.
Shockwave Therapy
For the inflammation and fibrotic adipose remodeling that characterize lipedema. A direct anti-inflammatory tool offered alongside FLIP.
IV Hydration Therapy
For the dysautonomic patient navigating early titration fluid shifts.
Prolotherapy & Orthobiologics
Access to dextrose prolotherapy and ProloBoost Dual PRP when joint instability becomes prominent during weight change.
Nutrition Consultation
Direct referral to an All-Star Nutrition consultation when indicated — often covered by insurance — for the protein and macronutrient planning that protects lean mass on GLP-1.
FIT GPS™
Optional genomic performance screen layered onto the FLIP baseline workup. Recommended for any patient on GLP-1 therapy.
Hypermobility & EDS Clinic
The physician-led 5-visit program for connective tissue conditions.
Who Runs It
A physician who has built his career around this exact patient.
Program Director
Jacques Courseault, MD, FAAPMR
Board-certified in Physical Medicine & Rehabilitation, with a decade of clinical focus on the fascial system, hypermobility spectrum disorders, mast cell activation, and the integrated care of patients with overlapping connective tissue and inflammatory disease.
Dr. Courseault developed Fascial Mapping® and Hydrofascia Release™, leads the Hypermobility & EDS Clinic at FIT, and treats this patient population every day. FLIP is the program he wished existed for his own patients.
Resources & Evidence
Related care, and the research behind FLIP.
Internal pages our FLIP patients reference most, and the peer-reviewed literature supporting the program’s clinical logic.
Related at The Fascia Institute
Other pages FLIP patients reference.
- Hypermobility & EDS Clinic
The physician-led 5-visit program for the overlapping connective-tissue conditions that FLIP integrates with.
- Fascial Mapping®
Full-body ultrasound assessment we use to document tissue organization through GLP-1 weight change.
- Hydrofascia Release™
For the myofascial restrictions and fascial pain that emerge as adipose tissue remodels.
- Shockwave Therapy
For the fibrotic adipose remodeling and inflammation that characterize lipedema.
- Prolotherapy & Orthobiologics
Available when joint instability becomes prominent during weight change.
- IV Hydration Therapy
Plasma-Lyte and Lactated Ringer’s hydration for the dysautonomic patient navigating early titration.
- FIT GPS™ Genomic Performance Screen
Optional but recommended companion to the FLIP baseline lab workup.
- Mast Cell Resources
Clinical writing on MCAS and the connective-tissue / immune overlap.
Research & Evidence
Peer-reviewed literature behind the program.
- Utility of GLP-1 Receptor Agonists in Mast Cell Activation Syndrome
American Journal of the Medical Sciences, 2025 · PMID 40675372 · Case series in 47 MCAS patients showing 89% clinical benefit.
- Lipedema and Hypermobility Spectrum Disorders Sharing Pathophysiology
Cross-Sectional Observational Study, 2025 · PMC12565064 · Documents the shared connective-tissue biology these patients carry.
- Lipedema and Adipose Tissue: Understanding, Controversies, and Future Directions
Frontiers in Cell and Developmental Biology, 2025 · Repositions lipedema as an inflammatory adipose disorder.
- Lipedema: A Disease Triggered by M2 Polarized Macrophages?
Biomedicines, 2025 · PMC11940465 · The macrophage and mast cell infiltration model.
- Unmasking Semaglutide-Induced Gastroparesis
Case Report, 2025 · PMC12497442 · The dangers of rapid dose escalation — why we under-titrate.
- Mast Cell Activation Syndrome: A Primer for the Practicing Clinician
Clinical Review, 2021 · PMID 34681933 · The clinical framework underpinning MCAS care at FIT.
- Full Clinical Commentary — Dr. Courseault
The longform clinical write-up: “GLP-1, Mast Cell Activation, and the Hypermobile Body.”
How to Start
Three steps. One conversation.
Request an evaluation.
Reach out through the appointment form or by phone. Our team will gather initial information to determine whether FLIP is a clinical fit.
Intake & baseline workup.
If indicated, you come in for a full evaluation: medical history, baseline body composition, baseline labs, and the program consent and financial agreement — all disclosed up front.
Begin under physician care.
Dose initiation, slow titration, monthly check-ins, OxeFit training, and the rest of the FLIP scaffolding — from week one.
Read the Science
The full clinical commentary on GLP-1 and the hypermobile body.
Dr. Courseault’s detailed clinical write-up on the biology, the recent literature, and the case for a connective-tissue-aware GLP-1 program.
Ready to Begin?
Have the conversation with the right physician.
If you are managing lipedema, hEDS, MCAS, or the overlap and you have been wondering whether GLP-1 therapy might help you, the conversation is worth having — just not with an app and a pen-shipment program.